Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is among the greatest small-cap biotech shares to purchase based on analysts.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) reported its Q3 2025 outcomes on November 6, 2025. The quarter marked continued development of its muscular dystrophy and cardiac applications. In the meantime, its important GRAND CANYON cohort for sevasemten in Becker muscular dystrophy stays well-positioned for readout in This autumn 2026. On the identical time, the MESA open-label extension trial famous continued enrollment of almost all eligible members. The quarter additionally noticed the Part 2 CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy progressing nicely, with a program replace anticipated in This autumn 2025. Part 1 dosing of EDG-15400 for coronary heart failure additionally kicked off.
Because of the medical exercise in EDC-15400, EDC-7500, and the sevasemten program, R&D bills surged by $3.9 million to $37.5 million, in comparison with the identical quarter a yr earlier. With G&A bills up $0.3 million sequentially, Edgewise Therapeutics, Inc. (NASDAQ:EWTX) recorded a web lack of $40.7 million, or $0.39 per share.
But Edgewise Therapeutics, Inc. (NASDAQ:EWTX) closed the quarter with $563.3 million in money balances, ample to supply a runway to assist ongoing medical growth and potential future business launches.
Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a biopharmaceutical firm, develops new therapies for muscular dystrophies and critical cardiac circumstances.
Whereas we acknowledge the potential of EWTX as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back threat. In case you’re searching for an especially undervalued AI inventory that additionally stands to learn considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 7 Finest Oil and Fuel Penny Shares to Purchase Based on Analysts and Billionaire Jacob Rothschild’s RIT Capital Companions: 9 Shares with Large Upside Potential.
Disclosure: None.
